Controversial research and trials aim to reverse clinical brain death and bring people back from irreversible coma.
Philadelphia-based biotech company Bioquark is preparing to run trials in Latin America of a controversial new treatment to restore brain function in people with brain damage.
The procedure consists of several different parts. One of which uses a patients own stem cells to regrow dead brain tissue. The procedure also includes a peptide injection into the spine, laser therapy on the brain, and nerve stimulation.
The first thing we are really looking at is how do we make that new tissue, along the lines of how it is done in nature, Ira Pastor, CEO of Bioquark, told Healthline.
Doctors and staff measure the brain activity and physical signs of the patient to establish whether or not there has been an improvement.
While the research has often been labeled as an attempt to raise the dead, Pastor said that there are actually significant limitations to the scope of what they are trying to accomplish.
We are only focusing on what we refer to as the gray zone that exists between [a] deep coma and so-called irreversible coma, which is the definition of brain death, and transitioning the subject back through that area, said Pastor.
Measure of an individuals state of coma or unconsciousness typically utilizes the Glasgow Coma Scale, an indicator of the severity based on verbal and physiological responses.
Bioquarks aim is essentially to be able to take individuals from a state of irreversible coma to, potentially, one in which they are showing higher brain functioning and physiological response.
He said that the treatment is not intended for individuals with catastrophic injuries, or those with chronic diseases, such as metastatic cancer.
Brain death is a relatively new concept in medicine and law, and still varies largely from one country to the next. Unlike clinical death, as defined by the stopping of certain biological functions such as breathing and heart rate brain death is a state in which an individual may still be physically alive but with little or no cognitive ability.
The concept of brain death is attributed to a 1968 paper from Harvard University that sought to define irreversible coma as a new criterion for death. Since then, legislation such as the Uniform Determination of Death Act, has sought to create a unified framework for how death is diagnosed, including brain death.
The implications of Bioquarks research potentially altering or muddying an already complex definition of death are profound. This study deepens the ambiguity of the validity of the definition of death, Kerry Bowman, PhD, a bioethicist at the University of Toronto, told Healthline.
Read more: Using stem cells to heal broken bones
The procedure has also proved wildly controversial for ethical and medical reasons.
Firstly, the research falls under the classification of living cadaver research, which Pastor describes as, The ability to use a recently deceased individual who is still on life support for medical research purposes.
Pastor argued previously that living cadaver research has been carried out ethically for a variety of reasons in the Unites States. Nonetheless, it remains a sensitive subject.
There are those in the medical community who criticize Bioquark because there simply isnt any medical research to support its work. One meta study published in the journal Neurology in 2010, concluded that from 1995 onward, There are no published reports of recovery of neurologic function after a diagnosis of brain death.
Pastor contests this, citing sporadic cases challenging that conclusion.
Read more: Stem cell therapy offers hop for MS remission
Bowman said the two major concerns surrounding Bioquarks work are family grief and patient consent.
In the first case, he said, the procedure could create a situation where [the family] believes that their brain-dead or close to brain-dead loved one has a chance for survival, and that the medical establishments are blocking them from pursuing that chance.
I think that really could be very difficult in terms of complicating grief.
The second issue, consent, is even more contentious. Who signs off on the procedure if the patient doesnt have the capacity to say Yes or No?
Clearly this is a case where the subject cannot consent, said Pastor. The informed consent documents that we have put together are really family centric.
There is a line of reasons why a family might want to come down this path, but ultimately its their decision.
Others disagree that consent in this situation is as clear as Pastor makes it.
Bowman said that the potential risk of such a procedure is so high that the consent must come directly from the patient.
The ranges of outcomes I see physical impairment and neurological impairment as almost a certainty even if there is success that I just dont think you could have a substituted consent.
Some have suggested that consent could be coerced under the proposition of bringing back a loved one.
Pastor, however, is confident in Bioquarks proceedings.
Of the multitude of different types of bioethical arguments or questions we get, I think were comfortable with that family-centric, informed consent approach, he said.
Whether or not Bioquark ultimately succeeds, their upcoming trials will undoubtedly have a profound impact on the concept of death.
Bowman, while skeptical of Bioquarks research from a medical perspective, is open to challenging the established notion of brain death.
There are places in the world that are much more hesitant about accepting brain death as truly death, he said. We constructed this as a definition of death, but we can also deconstruct a definition that we created ourselves.
As to the claim that Pastor and Bioquark are offering false hope to those that are already vulnerable and suffering, he remains defiant.
Exploratory research programs of this nature are not false hope. They are a glimmer of hope.
Read more: Stem cell research advancing rapidly
Go here to read the rest:
Are Stem Cells the Answer to Bringing People Back from the Dead? - Healthline
- Breast Cancer Is Most Common Cancer In India, 1.38 Million Cases Diagnosed Annually. Know Estimated Incidence By 2030 - ABP Live - November 26th, 2023
- What Is Amyloidosis? All About The Rare Disease That Pervez Musharraf Suffered From - ABP Live - February 8th, 2023
- Autophagic death of neural stem cells mediates chronic stress-induced ... - November 7th, 2022
- Programmed cell death - Wikipedia - November 7th, 2022
- Hematopoietic Stem Cells | Hematopoiesis | Properties & Functions - September 4th, 2022
- Canadian Blood Services Stem Cells for Life - September 4th, 2022
- Devastation over death of schoolgirl, 11, who hoped she was beating cancer - Leicestershire Live - September 4th, 2022
- From optimized stem cell transplants to CAR T cell therapy: Advancing options for cancer, HIV and more - City of Hope - September 4th, 2022
- Scientists unlock the key to immortality in jellyfish - Syfy - September 4th, 2022
- Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients... - September 4th, 2022
- Menin Inhibitors Have Potential to Become the Next Class of Targeted Therapy in AML - Targeted Oncology - September 4th, 2022
- Wanted murder suspect John Belfield believed to still be in the UK as two more arrested over death of Thomas Campbell - The Manc - September 4th, 2022
- Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study | Blood Cancer Journal... - July 8th, 2022
- Can minds persist when they are cut off from the world? - Livescience.com - July 8th, 2022
- Black Adolescent Young Adults With AML Have Worse Outcomes Vs White Population - Cancer Network - July 8th, 2022
- Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in... - July 8th, 2022
- How abortion ruling could affect IVF and embryonic research - The Almanac Online - July 8th, 2022
- This Morning viewers 'in tears' after boy meets donor who saved his life - Devon Live - July 8th, 2022
- Alpena detective: 'Good people out there' | News, Sports, Jobs - Alpena News - July 8th, 2022
- 'I miss my best friend': Five-year-old runs 10k to honour girl who died from rare brain tumour - Teesside Live - July 8th, 2022
- Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by... - July 8th, 2022
- Novartis AG, AstraZeneca Plc, and Pfizer Inc Among Leading Companies in the Thyroid Cancer Pipeline Products Market | Globaldata Plc - Yahoo Finance - July 8th, 2022
- A New Strategy Could Turn the Tide in Stem Cell GVHD - Medical Device and Diagnostics Industry - January 17th, 2022
- Vertex type 1 diabetes vs stem cell therapy - The Boar - January 17th, 2022
- Two-Year OS Doubles for Patients With Philadelphia-Positive Relapsed ALL After HSCT - AJMC.com Managed Markets Network - January 17th, 2022
- Nowakowski Considers CD19 Therapy in Transplant-Ineligible DLBCL - Targeted Oncology - January 17th, 2022
- Psaki demolishes Doocy with stats as he tries to claim covid now an illness of the vaccinated - newsconcerns - January 17th, 2022
- Doctors and Researchers Probe How COVID-19 Attacks the Heart - The Scientist - January 17th, 2022
- Who does donated blood that's direly needed help? - WTOP - January 17th, 2022
- Places Where Omicron is Most Contagious Eat This Not That - Eat This, Not That - January 17th, 2022
- UHN and U of T receive $24-million federal grant for transplant research - News@UofT - January 17th, 2022
- Glycyrrhizic acid ameliorates submandibular gland oxidative stress, autophagy and vascular dysfunction in rat model of type 1 diabetes | Scientific... - January 17th, 2022
- Stem cells in cancer therapy: opportunities and challenges - January 1st, 2022
- Life After Brain Death: Is the Body Still 'Alive'? | Live ... - January 1st, 2022
- Autologous Adult Stem Cells in the Treatment of Stroke | SCCAA - Dove Medical Press - January 1st, 2022
- Stem Cell Mimicking Nanoencapsulation for Targeting Arthrit | IJN - Dove Medical Press - January 1st, 2022
- Cellular Therapies Fill Unmet Needs in R/R Multiple Myeloma - Targeted Oncology - January 1st, 2022
- Upregulated expression of actin-like 6A is a risk factor | CMAR - Dove Medical Press - January 1st, 2022
- COVID-19 Takes a Toll on People with Blood Cancers and Disorders - Cancer Health Treatment News - January 1st, 2022
- Mental health disorders and heart diseases - Rising Kashmir - January 1st, 2022
- Research breakthrough could mean better treatment for patients with most deadly form of brain tumor - EurekAlert - October 26th, 2021
- European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable... - October 26th, 2021
- European Commission Selects Humanigen's Lenzilumab as One of the 10 Most Promising Treatments for COVID-19 - Galveston County Daily News - October 26th, 2021
- Everything You Need To Know About COVID Booster Shots - Colorado Times Recorder - October 26th, 2021
- Stem cells and their role in lung transplant rejection - Michigan Medicine - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- Will humans ever be immortal? - Livescience.com - October 5th, 2021
- Healthcare Researchers Are Putting HUMAN Immune Systems In Pigs To Study Illnesses-Here's The Tech Behind It - Tech Times - October 5th, 2021
- Why Bezos, Musk, Page and other billionaires want to live forever - New York Post - October 5th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - ABC 12 News - October 5th, 2021
- U.S. FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Business... - October 5th, 2021
- Skeletons' broken clavicles tell a centuries-old tale of humans and horses - Massive Science - October 5th, 2021
- Environmental Factor - August 2021: Extramural Papers of the Month - Environmental Factor Newsletter - August 4th, 2021
- Role of traumatic brain injury in the development of glioma | JIR - Dove Medical Press - August 4th, 2021
- Targeted Therapeutics Market: Increase in Incidence of Cancer to Drive Global Market - BioSpace - August 4th, 2021
- Accumulation of Regulatory T Cells in Triple Negative Breast Cancer Ca | CMAR - Dove Medical Press - August 4th, 2021
- Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients with Multiple Myeloma - Curetoday.com - June 7th, 2021
- Autophagy suppresses the formation of hepatocyte-derived cancer-initiating ductular progenitor cells in the liver - Science Advances - June 7th, 2021
- Cancer research: New advances and innovations - Medical News Today - June 7th, 2021
- Fulvestrant Alone Found to be Superior to Venetoclax/Fulvestrant Combo in ER+/HER2- Breast Cancer - Targeted Oncology - June 7th, 2021
- Merck's KEYTRUDA Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal... - June 7th, 2021
- Stem cell study illuminates the cause of an inherited heart disorder | Penn Today - Penn Today - February 14th, 2021
- The race to treat a rare, fatal syndrome may help others with common disorders like diabetes - Science Magazine - February 14th, 2021
- Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with... - February 14th, 2021
- The Very First Signs of an Immune Response Have Been Filmed in a Developing Embryo - ScienceAlert - February 14th, 2021
- Arlo's Army needs stem cell donor as mum begs for help to save three-year-old's life - Glasgow Live - February 14th, 2021
- Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV (enfortumab vedotin-ejfv) in Patients with Previously... - February 14th, 2021
- [Full text] Successful Use of Nivolumab in a Patient with Head and Neck Cancer Aft | OTT - Dove Medical Press - February 14th, 2021
- The drug treatments offering the best hope of a way out of the Covid crisis - Telegraph.co.uk - February 14th, 2021
- In the war against Covid, an arsenal of drugs is on the way - Telegraph.co.uk - February 14th, 2021
- Kat Wests husband, Jeff West, sentenced to 16 years in wifes death - AL.com - February 9th, 2021
- Harnessing the Potential of Cell and Gene Therapy - OncLive - February 9th, 2021
- I Survived Cancer, and Then I Needed to Remember How to Live - The Atlantic - February 9th, 2021
- [Full text] Higher Red Blood Cell Distribution Width is a Poor Prognostic Factor f | CMAR - Dove Medical Press - February 9th, 2021
- West Belfast woman to be remembered in special TV documentary - Belfast Live - January 29th, 2021
- UTV documentary tells of young Belfast woman's lasting legacy to promote stem cell donation - The Irish News - January 29th, 2021
- L-MIND Trial Results Show CD19 Antibody Is Reasonable in R/R DLBCL - Targeted Oncology - January 29th, 2021
- Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes... - January 29th, 2021
- If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine? - Kaiser Health News - January 29th, 2021
- Experimental taphonomy of organelles and the fossil record of early eukaryote evolution - Science Advances - January 29th, 2021